The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Intellia Therapeutics, Inc(NASDAQ:NTLA) 
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which i...
Website: http://www.intelliatx.com
Founded: 2014
Full Time Employees: 270
CEO: John Leonard
Sector: Healthcare
Industry: Biotechnology
Intellia Therapeutics Days Payable Outstanding ttm (DPO)
Intellia Therapeutics Days Receivable Outstanding ttm (DSO)
Intellia Therapeutics Op Cashflow Per Share ttm
Intellia Therapeutics Free Cashflow Per Share ttm
Intellia Therapeutics Cash Per Share ttm
Intellia Therapeutics P/S ratio ttm
Intellia Therapeutics (GAAP) P/E ratio ttm
Intellia Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.